Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1996 Jun 8;312(7044):1443–1448. doi: 10.1136/bmj.312.7044.1443

Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population.

P D Pharoah 1, W Hollingworth 1
PMCID: PMC2351181  PMID: 8664620

Abstract

OBJECTIVES--To estimate the cost effectiveness of statins in lowering serum cholesterol concentration in people at varying risk of fatal cardiovascular disease and to explore the implications of changing the criteria for intervention on cost and cost effectiveness for a purchasing authority. DESIGN--A life table method was used to model the effect of treatment with a statin on survival over 10 years in men and women aged 45-64. The costs of intervention were estimated from the direct costs of treatment, offset by savings associated with a reduction in coronary angiographies, non-fatal myocardial infarctions, and revascularisation procedures. The robustness of the model to various assumptions was tested in a sensitivity analysis. SETTING--Population of a typical district health authority. MAIN OUTCOME MEASURE--Cost per life year saved. RESULTS--The average cost effectiveness of treating men aged 45-64 with no history of coronary heart disease and a cholesterol concentration > 6.5 mmol/l for 10 years with a statin was 136,000 pounds per life year saved. The average cost effectiveness for patients with pre-existing coronary heart disease and a cholesterol concentration > 5.4 mmol/l was 32,000 pounds. These averages hide enormous differences in cost effectiveness between groups at different risk, ranging from 6000 pounds per life year in men aged 55-64 who have had a myocardial infarction and whose cholesterol concentration is above 7.2 mmol/l to 361,000 pounds per life year saved in women aged 45-54 with angina and a cholesterol concentration of 5.5-6.0 mmol/l. CONCLUSIONS--Lowering serum cholesterol concentration in patients with and without preexisting coronary heart disease is effective and safe, but treatment for all those in whom treatment is likely to be effective is not sustainable within current NHS resources. Data on cost effectiveness data should be taken into account when assessing who should be eligible for treatment.

Full text

PDF
1443

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Burr M. L., Fehily A. M., Gilbert J. F., Rogers S., Holliday R. M., Sweetnam P. M., Elwood P. C., Deadman N. M. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989 Sep 30;2(8666):757–761. doi: 10.1016/s0140-6736(89)90828-3. [DOI] [PubMed] [Google Scholar]
  2. Frost P. H., Verter J., Miller D. Serum lipids and lipoproteins after myocardial infarction: associations with cardiovascular mortality and experience in the Aspirin Myocardial Infarction Study. Am Heart J. 1987 Jun;113(6):1356–1364. doi: 10.1016/0002-8703(87)90648-x. [DOI] [PubMed] [Google Scholar]
  3. Grodos D., Tonglet R. Scandinavian simvastatin study (4S) Lancet. 1994 Dec 24;344(8939-8940):1768–1768. [PubMed] [Google Scholar]
  4. Martens L. L., Guibert R. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Clin Ther. 1994 Nov-Dec;16(6):1052–1036. [PubMed] [Google Scholar]
  5. Martin M. J., Hulley S. B., Browner W. S., Kuller L. H., Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet. 1986 Oct 25;2(8513):933–936. doi: 10.1016/s0140-6736(86)90597-0. [DOI] [PubMed] [Google Scholar]
  6. Pekkanen J., Linn S., Heiss G., Suchindran C. M., Leon A., Rifkind B. M., Tyroler H. A. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 1990 Jun 14;322(24):1700–1707. doi: 10.1056/NEJM199006143222403. [DOI] [PubMed] [Google Scholar]
  7. Rose G., Shipley M. Plasma cholesterol concentration and death from coronary heart disease: 10 year results of the Whitehall study. Br Med J (Clin Res Ed) 1986 Aug 2;293(6542):306–307. doi: 10.1136/bmj.293.6542.306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Sawitz E., Showstack J. A., Chow J., Schroeder S. A. The use of in-hospital physician services for acute myocardial infarction. Changes in volume and complexity over time. JAMA. 1988 Apr 22;259(16):2419–2422. [PubMed] [Google Scholar]
  9. Sculpher M. J., Seed P., Henderson R. A., Buxton M. J., Pocock S. J., Parker J., Joy M. D., Sowton E., Hampton J. R. Health service costs of coronary angioplasty and coronary artery bypass surgery: the Randomised Intervention Treatment of Angina (RITA) trial. Lancet. 1994 Oct 1;344(8927):927–930. doi: 10.1016/s0140-6736(94)92274-8. [DOI] [PubMed] [Google Scholar]
  10. Shaper A. G., Pocock S. J., Walker M., Phillips A. N., Whitehead T. P., Macfarlane P. W. Risk factors for ischaemic heart disease: the prospective phase of the British Regional Heart Study. J Epidemiol Community Health. 1985 Sep;39(3):197–209. doi: 10.1136/jech.39.3.197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Sheldon T. A. Discounting in health care decision-making: time for a change? J Public Health Med. 1992 Sep;14(3):250–256. [PubMed] [Google Scholar]
  12. Shepherd J., Cobbe S. M., Ford I., Isles C. G., Lorimer A. R., MacFarlane P. W., McKillop J. H., Packard C. J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 Nov 16;333(20):1301–1307. doi: 10.1056/NEJM199511163332001. [DOI] [PubMed] [Google Scholar]
  13. Suhonen O., Reunanen A., Knekt P., Aromaa A. Risk factors for sudden and non-sudden coronary death. Acta Med Scand. 1988;223(1):19–25. doi: 10.1111/j.0954-6820.1988.tb15760.x. [DOI] [PubMed] [Google Scholar]
  14. Ulvenstam G., Bergstrand R., Johansson S., Vedin A., Wilhelmsson C., Wedel H., Aberg A., Wilhelmsen L. Prognostic importance of cholesterol levels after myocardial infarction. Prev Med. 1984 Jul;13(4):355–366. doi: 10.1016/0091-7435(84)90027-6. [DOI] [PubMed] [Google Scholar]
  15. de Lorgeril M., Renaud S., Mamelle N., Salen P., Martin J. L., Monjaud I., Guidollet J., Touboul P., Delaye J. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet. 1994 Jun 11;343(8911):1454–1459. doi: 10.1016/s0140-6736(94)92580-1. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES